With rapidly expanding genetic correction methods, iPSC-derived (cardio)myocytes (with restored dystrophin expression and/or modification of secondary pathophysiological pathways) may constitute new options for DMD treatment by autologous transplantation. Here, DMD is linked to Duchenne muscular dystrophy.